Image pharmaphorum Editor Patients Sponsored Measuring the intangible – what is the true value of a “pati... Views & Analysis Capturing progress in haemophilia care If we look back just 70 years, the prognosis for patients with haemophilia was remarkably different to what it is today. Views & Analysis Artificial Intelligence for better antibody drugs: ready for... The potential of monoclonal antibodies (mAbs) as therapies is indisputable. The current mAbs market is expected to be around ~USD 150 billion. Sales & Marketing Sponsored Unlocking the full power of data for Pharma The value of data has never been greater in healthcare. Load more results
Views & Analysis Capturing progress in haemophilia care If we look back just 70 years, the prognosis for patients with haemophilia was remarkably different to what it is today.
Views & Analysis Artificial Intelligence for better antibody drugs: ready for... The potential of monoclonal antibodies (mAbs) as therapies is indisputable. The current mAbs market is expected to be around ~USD 150 billion.
Sales & Marketing Sponsored Unlocking the full power of data for Pharma The value of data has never been greater in healthcare.
News Court sides with EU on decision to revoke Ocaliva's license Advanz Pharma's bid to keep its Ocaliva treatment for rare liver disease primary biliary cholangitis (PBC) on the EU market has ended in failure
Sales & Marketing Coming soon: The Life Sciences Industry Report 2025 – insigh... Prepare for 2025 with pharmaphorum’s Life Sciences Report, featuring expert insights on AI in drug development, gene therapy, and top industry trends
